Efficacy of Carfilzomib in the Treatment of Relapsed and (or) Refractory Multiple Myeloma: a Meta-analysis of Data from Clinical Trials

被引：1

作者：

Chen, Runzhe ^{[1
]}

Chen, Baoan ^{[1
]}

Zhang, Xiaoping ^{[1
]}

Gao, Chong ^{[1
]}

机构：

[1] Southeast Univ, Med Sch, Zhongda Hosp, Dept Hematol & Oncol,Key Dept Jiangsu Med, Nanjing 210009, Jiangsu, Peoples R China

来源：

DISCOVERY MEDICINE | 2016年 / 22卷 / 121期

基金：

中国国家自然科学基金;

关键词：

SINGLE-AGENT CARFILZOMIB; LOW-DOSE DEXAMETHASONE; OPEN-LABEL; PHASE-II; LENALIDOMIDE; THALIDOMIDE; SAFETY; ARM; CYCLOPHOSPHAMIDE; THERAPY;

D O I：

暂无

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Recently, carfilzomib has become a promising therapeutic approach for relapsed and (or) refractory multiple myeloma (RRMM), but no study has summarized the overall effect of carfilzomib in RRMM. To explore the role of carfilzomib, we performed a meta- analysis of all known prospective clinical trials to assess the efficacy of carfilzomib in patients with RRMM. Methods and Materials: A systematic review of publications was performed on December 15, 2015. Eight studies including 1,446 patients were identified. Meta- analyses were carried out to calculate the overall response rate (ORR), complete response rate (CRR), and clinical benefit rate (CBR) of carfilzomib for RRMM. Results: In patients with RRMM, ORR was 0.44, CRR was 0.13, and CBR was 0.54. High heterogeneity between studies was observed, and funnel plots were symmetrical, negating publication bias. Carfilzomib was generally well tolerated by patients reported in the studies though some manageable adverse effects occurred. Conclusion: Our analysis revealed a promising benefit of carfilzomib in the treatment of RRMM.

引用

页码：189 / 199

页数：11

共 29 条

[1] A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma [J].

Alsina, Melissa ;

Trudel, Suzanne ;

Furman, Richard R. ;

Rosen, Peter J. ;

O'Connor, Owen A. ;

Comenzo, Raymond L. ;

Wong, Alvin ;

Kunkel, Lori A. ;

Molineaux, Christopher J. ;

Goy, Andre .

CLINICAL CANCER RESEARCH, 2012, 18 (17) :4830-4840

[2] Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety [J].

Badros, A. Z. ;

Vij, R. ;

Martin, T. ;

Zonder, J. A. ;

Kunkel, L. ;

Wang, Z. ;

Lee, S. ;

Wong, A. F. ;

Niesvizky, R. .

LEUKEMIA, 2013, 27 (08) :1707-1714

[3] Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study [J].

Bringhen, Sara ;

Petrucci, Maria Teresa ;

Larocca, Alessandra ;

Conticello, Concetta ;

Rossi, Davide ;

Magarotto, Valeria ;

Musto, Pellegrino ;

Boccadifuoco, Luana ;

Offidani, Massimo ;

Omede, Paola ;

Gentilini, Fabiana ;

Ciccone, Giovannino ;

Benevolo, Giulia ;

Genuardi, Mariella ;

Montefusco, Vittorio ;

Oliva, Stefania ;

Caravita, Tommaso ;

Tacchetti, Paola ;

Boccadoro, Mario ;

Sonneveld, Pieter ;

Palumbo, Antonio .

BLOOD, 2014, 124 (01) :63-69

[4] Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity [J].

Cornell, R. F. ;

Kassim, A. A. .

BONE MARROW TRANSPLANTATION, 2016, 51 (04) :479-491

[5] Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study [J].

Dimopoulos, Meletios A. ;

Moreau, Philippe ;

Palumbo, Antonio ;

Joshua, Douglas ;

Pour, Ludek ;

Hajek, Roman ;

Facon, Thierry ;

Ludwig, Heinz ;

Oriol, Albert ;

Goldschmidt, Hartmut ;

Rosinol, Laura ;

Straub, Jan ;

Suvorov, Aleksandr ;

Araujo, Carla ;

Rimashevskaya, Elena ;

Pika, Tomas ;

Gaidano, Gianluca ;

Weisel, Katja ;

Goranova-Marinova, Vesselina ;

Schwarer, Anthony ;

Minuk, Leonard ;

Masszi, Tamas ;

Karamanesht, Ievgenii ;

Offidani, Massimo ;

Hungria, Vania ;

Spencer, Andrew ;

Orlowski, Robert Z. ;

Gillenwater, Heidi H. ;

Mohamed, Nehal ;

Feng, Shibao ;

Chng, Wee-Joo .

LANCET ONCOLOGY, 2016, 17 (01) :27-38

[6] A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma [J].

Glasmacher, A ;

Hahn, C ;

Hoffmann, F ;

Naumann, R ;

Goldschmidt, H ;

Lilienfeld-Toal, M ;

Orlopp, K ;

Schmidt-Wolf, I ;

Gorschlüter, M .

BRITISH JOURNAL OF HAEMATOLOGY, 2006, 132 (05) :584-593

[7] Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM) [J].

Hajek, Roman ;

Bryce, Richard ;

Ro, Sunhee ;

Klencke, Barbara ;

Ludwig, Heinz .

BMC CANCER, 2012, 12

[8]

Higgins JPT, 2011, Cochrane handbook for systematic reviews for interventions

[9] An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma [J].

Jagannath, Sundar ;

Vij, Ravi ;

Stewart, A. Keith ;

Trudel, Suzanne ;

Jakubowiak, Andrzej J. ;

Reiman, Tony ;

Somlo, George ;

Bahlis, Nizar ;

Lonial, Sagar ;

Kunkel, Lori A. ;

Wong, Alvin ;

Orlowski, Robert Z. ;

Siegel, David S. .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2012, 12 (05) :310-318

[10]

Khan ML, 2011, FUTURE ONCOL, V7, P607, DOI [10.2217/FON.11.42, 10.2217/fon.11.42]

← 1 2 3 →